Skip to main content
LMRI logo

LMRI · Lumexa Imaging Holdings, Inc. · Financials

Track LMRI — free
$11.67 -0.07 (-0.60%) Q2 2026 earnings call transcript
Market Cap
$1.13B
Shares
96.07M
Volume · Oct 27 342.43K Avg daily vol (3M) 417.85K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Chart any reported metric, KPI or segment over time — the full statement history lives here

No structured figures reported for this view yet.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current finance lease liabilities 2026-06-30 USD 14,597,000 10-Q filed 2026-08-13
Current operating lease liabilities 2026-06-30 USD 11,932,000 10-Q filed 2026-08-13
Long-term debt, including current maturities 2026-06-30 USD 835,350,000 10-Q filed 2026-08-13
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current portion of long-term debt
USD 14,330,000
Noncurrent debt carrying amount
USD 819,753,000
Noncurrent finance lease liabilities 2026-06-30 USD 41,177,000 10-Q filed 2026-08-13
Noncurrent operating lease liabilities 2026-06-30 USD 72,296,000 10-Q filed 2026-08-13
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
—
Peer median 2.99×
EV/EBIT
—
Peer median 23.54×
P/E (TTM)
—
Peer median 27.39×
EV/Adj. EBITDA (FY2025)
8.22×
Peer median 16.68×

Peer medians compare against the 66 similar-size Medical Devices companies (of 156 listed).

EV/Adj. EBITDA uses the company-stated “Adjusted EBITDA”, extracted from the reconciliation in its SEC filings — the company's own non-GAAP definition, not an XBRL-tagged figure.

Valuation over time computed as of each quarter's filing date

EV/Adj. EBITDA uses the company-stated “Adjusted EBITDA”, extracted from the reconciliation in its SEC filings as it existed at each sample date — the company's own non-GAAP definition, not an XBRL-tagged figure. Each point's tooltip names its TTM or fiscal-year basis.

Key facts CIK 2071288 CUSIP 550249106 13F (30d) 12 filings 12 filers Visit website Investor relations